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Objective.—To assess the association between first myocardial infarction and
the use of antihypertensive agents.
Design and Setting.—We conducted a population-based case-control study
among enrollees of the Group Health Cooperative of Puget Sound (GHC).
Patients and Methode.—Gases were hypertensive patients who sustained a
first fatal or nonfatal myocardial infarction from 1986 through 1993 among women
and from 1989 through 1993 among men. Controls were a stratified random sample
of hypertensive GHC enrollees, frequency matched to the cases on age, sex, and
calendar year. All 623 cases and 2032 controls had pharmacologically treated hy-
pertension. Data collection included a review of the ambulatory medical record and
a brief telephone interview of consenting survivors. Antihypertensive therapy was
assessed usmg the GHC's computerized pharmacy database.
Results.—The first analysis included only the 335 cases and 1395 controls mi-
tially free of cardiovascular disease. Compared with users of diuretics alone, the
adjusted risk ratio of myocardial infarction was increased by about 60% among us-
ers of calcium channel blockers with or without diuretics (risk ratio=1.62; 95% con-
fidence interval [Cl], 1.11 to 2.34; P=.01). The second analysis was restricted to 384
cases and 1108 controls who were taking either a calcium channel blocker or a
ß-blocker. Among these subjects, the use of calcium channel blockers compared
with ß-blockers was associated with about a 60% increase m the adjusted risk of
myocardial infarction (risk ratio=1.57; 95% Cl, 1.21 to 2.04; P<.001). While high
doses of ß-blockers were associated with a decreased risk of myocardial infarction
(trend P=.04), high doses of calcium channel blockers were associated with an in-
creased risk (trend P<.01).
Conclusions.—In this study of hypertensive patients, the use of short-acting
calcium channel blockers, especially in high doses, was associated with an
increased risk of myocardial infarction. Ongoing large-scale clinical tnals will assess
the effect of various antihypertensive therapies, mcludmg calcium channel block-
ers, on several important cardiovascular end pomts. Until these results are avail-
able, the findings of this study Support the current guidelines from the Jomt National
Committee on the Detection, Evaluation and Treatment of High Blood Pressure that
recommend diuretics and ß-blockers äs first-line agents unless contraindicated,
unacceptable, or not tolerated.
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THE JOINT National Committee (JNC)
on the Detection, Evaluation and Treat-
ment of High Blood Pressure currently
recommcnds diuretics or ß-blockers äs
first-line drug therapy for hypertension.1
Low-dose diuretic therapy is not only
safe2 but also effective in preventing
stroke, myocardial infarction, congestive
heart failure, and total mortality.! r>
During the 1980s, calcium channel
blockers and angiotensin-converting en-
zyme (ACE) inhibitors were approved
for the treatmcnt of hypertension based
on the Surrogate end point of lowering
blood pressure. In the last decade, their
use has increased dramatically,1'"' although
the clinical trials evaluating these agents
against end points such äs left ventricu-
lar mass1"'1 and quality of life'11" do not
suggest a major advantage. In terms of
their effect on major-disease end points
such äs myocardial infarction and mor-
tality, calcium channel blockers and ACE
For editorial comment see p 654.
inhibitors have been evaluated only in the
secondary prevention trials of patients
with coronary disease" " or congestive
heart failure.14 ] ' The results of the sec-
ondary prevention randomized clinical tri-
als comparing calcium channel blockers
with placebo suggest the possibility of
härm, especially for the short-acting di-
hydropyridine class.121 1('17 In one recent
meta-analysis,1 '· mortality was signifi-
cantly increased, and there was a strong
linear relationship between the dose of
nifedipine and the risk of mortality (P=.01).
Whether similar adverse effects appear
among patients with high blood pressure
remains untested although several clini-
cal trials are in progress.ls Ά
To assess the association between an-
tihypertensive therapy and the incidence
of myocardial infarction, we conducted
a population-based case-control study.
Based on the results of the secondary
prevention trials,11 we had hypothesized
the possibility of an adverse effect of
calcium channel blockers.
METHODS
Setting
The setting was the Group Health Co-
operative of Puget Sound (GHC), Seattle,
Wash. The GHC recommendations con-
cerning antihypertensive therapy follow
the JNC,1 -- and the guidelines of the fourth
report of the JNC (1988 through 1993), in
effect during most of the study periocl,
recommended calcium channel blockers
äs one of the initial therapies for hyper-
tension.2- While all major classes of anti-
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hypertensive agents were well repre-
sented at the GHC, only the short-acting
formulations of the calcium channel block-
ers were available for routine use.
Identification of Cases and Controls
Gases were the GHC enrollees, aged 30
to 79 years, who had pharmacologically
treated hypertension and who were di-
agnosed with an incident fatal or nonfatal
myocardial infarction during July 1989
through December 1993. A companion
study of hormone replacement therapy23
used identical methods and allowed us to
inclucle 208 female hypertensive controls
and 112 cases diagnosecl during July 1986
through June 1989. We identified poten-
tial cases from (1) the computerized dis-
charge abstracts for the two GHC hospi-
tals; (2) the bills for out-of-plan Services
provided by non-GHC physicians and
health care facilities; and (3) the results of
a computerized match between the GHC
enrollment files and the Washington State
death registry files. We have used these
methods in previous studies.23 2!i In a
blinded validation study,23 the estimated
completeness of case ascertainment was
high (95%), and 97% of eligible cases met
Standard criteria for definite or probable
myocardial infarction.
Controls were a stratified random
sample of GHC enrollees with pharma-
cologically treated hypertension, and
they were frequency matched to the
cases by sex, age (within decade), and
calendar year at a ratio of between 2:1
and 3:1. Controls met the same eligibil-
ity criteria äs the cases, but they did not
have a myocardial infarction.
Index Oates and Eligibility
All subjects had an index date. For the
hospitalized cases, the index date was the
date of admission for the first myocardial
infarction; for the out-of-hospital fatal
cases, the index date was the date of death;
and for the controls, the index date was a
computer-generated random date within
the calendar year for which they had been
sampled äs controls. For all subjects, we
collected Information about eligibility and
risk factor data available only before the
index date. We excluded subjects (1) who
were enrollees for less than l year or who
had had fewer than four visits before their
index dates; (2) who did not have a diag-
nosis of hypertension in their medical re-
cord; (3) who had had a prior myocardial
infarction; and (4) whose myocardial in-
farction was a complication of a procedure
or surgery.
Data Collection and Definition
of Antihypertensive Drug Use
Data collection included a review of the·
GHC ambulatory medical record and a
telephone interview of consenting survi-
vors. Based on the medical record, trained
research assistants determined eligibility
and collected Information about traditional
risk factors for coronary heart disease,
such äs blood pressure, smoking, angina,
diabetes, and cholesterol. The telephone
interview sought similar Information about
risk factors, such äs smoking status, physi-
cal activity, education, and race. It was
not practicable to blind research assis-
tants to case-control status. Although they
knew the study involved hypertension,
they were not told about the hypotheses
related to specific antihypertensive drug
therapies.
The GHC computerized pharmacy da-
tabase was used to assess antihyper-
tensive drug therapies. Each pharmacy
record includes the drug type and dose,
quantity dispensed, date, and dosing in-
structions. When the dosing instructions
were missing from the pharmacy data,
we used the instructions available in the
medical record. For determining use on
a particular date, we searchecl the phar-
macy data for the antihypertensive drug
prescription immediately preceding that
date: when a subject, who was assumed
to be at least 80% compliant, received
enough pills to last until the date of in-
terest, that person was counted äs a
Potential current user on that date. This
process was repeated to determine use
at 30 and 60 days before the index date.
Because of concerns about the poten-
tial confounding effects of recently start-
ing drug therapies, a current user was
defined äs a subject who was a user not
only on the index date, but also for at least
30 days before the index date. This re-
quirement for a minimum duration of use
permitted us to exclude recent Starters,
whose drug course was prescribed within
30 days of the index date. In preliminary
analyses, recent starting of ß-blockers and
calcium channel blockers was strongly as-
sociated with the risk of myocardial in-
farction (risk ratio=2.68 and 2.52, respec-
tively; P<.01). The recent starting of these
drugs, which are also indicated for the
treatment of angina, is likely to be a
marker of suspected coronary disease,2"
and inclucling recent Starters äs if they
had been regulär users might have intro-
duced bias through confounding by the
secondary indication of angina.
In dose-response analyses, we used
the distribution of total daily doses to
define three groups of approximately
equal size. Subjects taking the modal
dose comprised the micldle group, and
subjects taking more or less than the
modal dose formed the other two groups.
The modal daily doses were 30 mg for
nifedipine, 180 mg for diltiazem hydro-
chloride, 240 mg for verapamil hydro-
chloride, 80 mg for propranolol hydro-
chloride, 100 mg for metoprolol tartrate,
80 mg for nadolol, and 50 mg for ateno-
lol. In terms of their effects on blood
pressure, these doses are approximately
equivalent to one another.2'1'27
Statistical Analysis
Data were complete for case-control Sta-
tus and the variables defining current drug
use. Medical conditions were uniformly
available, while recent blood pressures
and laboratory values were available for
96.2% to 100% of the subjects. For con-
tinuous data with less than 5% missing
data, we imputed the case-control and sex-
specific means. In preliminary analyses of
categorical data, the agreement between
medical-record and self-reported mea-
sures was good to excellent. Self-reported
data, if available, were used; if not, then
data from the medical record were used
äs covariates in analyses. For these com-
bined categorical variables, data were
missing on race (5.1%), smoking (1.3%),
and physical activity (7.2%). In sensitivity
analyses, coding of missing data äs one
value or another value for the categorical
variables had trivial effects on the results.
Data were also missing on cholesterol
(8.5%), duration of hypertension (6.9%),
and pretreatment blood pressure (33%),
largely for subjects who had begun anti-
hypertensive therapy before joining the
GHC. For these continuous covariates,
we used linear regression to estimate the
missing data, and in sensitivity analyses,
the confounding effects of covariates were
small and similar to those seen in the analy-
sis of subjects with complete data.
All statistical tests were two tailed. We
used stratification and logistic regression
to control for potential confounding fac-
tors and to estimate risk ratios.28·29
To assess the association of antihyper-
tensive drug therapies with myocardial
infarction, we used two approaches. In
the first, we excluded subjects with clini-
cal cardiovascular disease (CVD), defined
äs possible, probable, or definite diagnoses
of angina, stroke, or claudication; history
of coronary angioplasty, coronary bypass
surgery, peripheral vascular surgery, or
carotid endarterectomy; and receipt of a
prescription for nitroglycerin within 90
days of the index date. (Subjects with
congestive heart failure or a previous myo-
cardial infarction were not eligible.)
Among subjects free of clinical CVD (other
than hypertension), single-drug users of
cliuretics served äs the reference group,
and we created indicator variables for each
of the other major single-drug and two-
drug combinations. In the second ap-
proach, subjects were included only if they
were users of either ß-blockers or calcium
channel blockers. In these analyses, which
were stratified on the presence or absence
of CVD, users of ß-blockers served äs the
reference group.
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Table 1 —Charactenstics of Gases and Controls'
Charactenstic
Cases
(n=623)
Controls
(n=2023)
666 662
Most recent blood pressure
Systolic, mm Hg 1485 1440t
Diastolic, mm Hg 84 1 836
Pretreatment blood pressure
Systolic, mm Hg 1702 1648t
Diastolic, mm Hg
Duration of hypertension, y
Visits m last year, No
Time m Group Health, y
Antihypertensive medicmes, No
Cholesterol, mmol/L (mg/dL)
Glucose, mmol/L (mg/dL)
Afncan American, %
Males, %
Less than high school %
Current smoking, %
Not sedentary, %
Diabetes, %
Angina, %
Stroke history, %
Claudication, %
Coronary bypass surgery, %
Coronary angioplasty, %
Carotid endarterectomy %
Penpheral vascular surgery, %
Any cardiovascular disease, %
1004
121
77
159
1 5
6 52 (251 7)
719(1295)
34
509
493
260
567
279
284
82
101
35
1 1
4 2
37
41 6
1002
11 1t
63t
169
1 4
6 08 (234 9)t
640 (1154)t
4 4
632t
383t
137t
71 4t
133t
144t
66
50t
2 5
08
1 4t
20t
240t
Values are expressed äs means unless otherwise mdicated
tP·^  05 for companson of cases and controls
Table 2 —Proportions of Current Users of Vanous Drugs Among Control Subjects With and Without
Indications or Relative Contramdications to Specific Antihypertensive Therapies (Adjusted for Age, Sex, and
Calendar Year)1
Characteristic
Smoking Status
Nonsmoker
Smoker
P
Diabetes
None
Borderline
Definite
P
No.
1754
278
1762
73
197
Diuretics
546
582
24
564
504
533
42
[5-Blockers
337
354
60
345
306
254
03
Calcium
Channel Angiotensm-Converting
Blockers Enzyme Inhibitors
232
245
64
22 5
334
320
01
197
197
99
183
28 1
260
01
Cholesterol, mmol/L (mg/dL)
6 21 (240) 1169 562 334 188
--6 21 (240) 863 550 34 1 243 203
58 73 60 40
Clmical cardiovascular disease
No 1545 57 1 309 197 196
Yes 487 525 41 2 374 183
07 01 01 53
' Percentages are "row1 percentages for mstance, 54 6% of nonsmokers used diuretics, 58 2% of smokers used
diuretics, and the difference between the two proportions was not statistically significant (P= 24)
RESULTS
During· the study period, 930 hyper-
tcnsive patients were hospitalizecl for or
died out-of-hospital i'rom a first myocar-
dial infarction. We also identified 2598
population-based controls. In this analy-
sis, we cxcluded (1) 20 cases and 99 con-
trols who refused participation; (2) 103
cases and 113 controls who had conges-
tivc heart failure; (3) 150 cases and 331
controls who were not sufficiently com-
pliant with their medications to be clas-
sified äs current users of an antihyper-
tensive medication; and (4) 34 cases and
23 controls who were recent Starters of
ß-blockers or calcium channel blockers.
As a result, this study included 623 cases
and 2032 controls with pharmacologically
treated hypertension.
The time enrolled in the GHC, pretreat-
ment diastolic blood pressures, and re-
cent diastolic blood pressures (Table 1)
were similar in cases and controls. Cases
differed from controls for a number of
traditional risk factors, including systolic
blood pressure (Table 1).
Antihypertensive therapies have a va-
riety of adverse effects and relative con-
traindications that may affect the choice
of therapy. ß-Blockers are relatively con-
traindicated in patients with reactive air-
way disease, which is often associated with
smoking. In short-term studies,1" diuret-
ics and ß-blockers reportedly have ad-
verse effects on lipid levels. Among con-
trols (Table 2), the use of ß-blockers was
similar in smokers (35.4%) and nonsmok-
ers (33.7%), and the use of all antihyper-
tensive agents was similar among sub-
jects with and without elevated levels of
cholesterol. The use of both calcium chan-
nel blockers and ß-blockers was, however,
strongly associated with the secondary
indication of preexisting CVD, primarily
angina (P<.001).
The initial analysis was restricted to
the 335 cases and 1395 controls who were
free of clinical CVD and who were taking
either one of the major single drugs or
one of the major two-drug combinations
(Figure 1). The levels of treated systolic
and diastolic blood pressure were com-
parable among the rane drug giOups. The
risk ratios in Figure l were adjusted for
age, sex, calendar year, smoking, diabe-
tes, pretreatment systolic blood pressure,
duration of hypertension, education, and
physical activity. Compared with the use
of diuretics alone, the use of calcium chan-
nel blockers, with or without diuretics,
was associated with a 58% to 70% increase
in the risk ratio for myocardial infarction
(Figure 1). Treating calcium channel block-
ers äs a single variable, with or without
diuretics, yielded an adjusted risk ratio of
1.62 (95% confidence interval [CI], 1.11 to
2.34; P=.01).
Figure 2 represents the association of
myocardial infarction with the dose of
calcium channel blockers among subjects
free of clinical CVD. As dose increasecl,
so diel the level of risk even aller ad~
justment for potential confounding fac-
tors. The tests for trend in dose of cal-
cium channel blockers, both alone and in
combination with diuretics, were highly
significant (_P<.01).
The second analysis was restricted to
the 384 cases and 1108 controls who were
taking either a calcium channel blocker or
a ß-blocker. After adjustment, the use of
calcium channel blockers compared with
ß-blockers was associated with an in-
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creased risk of myocardial infarction both
among subjects with C VD (risk ratio=1.61;
95% CI, 1.07 to 2.42) and among those
without CVD (risk ratio=1.60; 95% CI,
1.12 to 2.27). For all hypertensive patients
combined—those with and without
CVD—the adjusted risk of myocardial in-
farction associated with the use of cal-
cium channel blockers compared with
ß-blockers was 1.57 (95% CI, 1.21 to 2.04;
P<.001). The adjusted risk ratios for in-
dividual calcium channel blockers were
similar: for nifedipine, 1.31 (95% CI, 0.85
to 2.01; P=.22); for diltiazem, 1.63 (95% CI,
1.06 to 2.50; P=.03); and for verapamil,
1.61 (95% CI, 1.19 to 2.17; P<.01). These
risk ratios did not differ significantly from
one another.
Figure 3 represents the results of the
dose-response analysis for the compari-
son of calcium channel blockers and
ß-blockers. The findings were similar
among hypertensive patients with and
without CVD. Low-dose users of ß-block-
ers served äs the reference group. As the
dose of ß-blockers increased, the adjusted
risk ratios decreased to 0.88 and 0.73 for
the medium-dose and high-dose ß-block-
ers groups, respectively. In contrast, äs
the dose of calcium channel blockers in-
creased, so did the adjusted risk ratios
for myocardial infarction—from 1.13 to
1.42 and up to 1.81 for the three dosage
groups. Not only were these dose-re-
sponse trends in the opposite direction,
but the tests for trend were also both
statistically significant (P<.05). Dose-re-
sponse analyses for the individual drugs
showed a similar pattern among subjects
with and without CVD.
The risk ratios of myocardial infarc-
tion associated with the use of calcium
channel blockers compared with ß-block-
ers were similar in a variety of sub-
groups: 1.72 for age younger than the
sex-specific median vs 1.53 for age
greater than or equal to the median;
1.72 for nondiabetics vs 1.08 for diabet-
ics; 1.51 for women vs 1.65 for men; 1.53
for nonsmokers vs 1.86 for current smok-
ers; and 1.64 for the 80th percentile or
less of creatinine vs 1.39 for greater than
the 80th percentile. The P values for the
statistical test of a difference between
the pairs of risk ratios were 0.41 for age,
0.28 for diabetes, 0.44 for sex, 0.95 for
smoking status, and 0.46 for renal func-
tion.
In other analyses, adjustment for ad-
ditional factors—cholesterol, glucose, po-
tassium, height and weight, family his-
tory, self-reported aspirin use, income,
race, employment, occupation, marital
status, pretreatment diastolic blood
pressure, treated systolic blood pres-
sure, and treated diastolic blood pres-
sure—had trivial effects on the findings.
The use of various alternative defini-
Drug
No. of
Cases
No. of
Controls
Adjusted
RR (95% CI)
Adjusted
RR and 95% CI
Treatment
, Better
Treatmont
Worse v
Diuretics 99
ß-Blockers
Alone 51
With Diuretics 34
452
234
161
Calcium Channel Blockers
Alone 56 170
With Diuretics 24 60
ACE Inhibitors
Alone 32 159
With Diuretics 10 66
Vasodilators
Alone 16 43
With Diuretics 13 50
1.0 (Reference)
1.09(0.74-1.63)
0.97(0.62-1.52)
1.58 (1.04-2.39)
1.70(0.97-2.99)
1.01 (0.62-1.62)
0.66(0.32-1.37)
1.53(0.79-2.97)
0.91 (0.46-1.83)
05 1.0 1.5 3.0
Figure 1 —Association between myocardial infarction and antihypertensive drug therapies among subjects
without any clinical cardiovascular disease. RR mdicates risk ratio (boxes); CI, confidence interval (cross bars);
ACE, angiotensm-converting enzyme. The RRs were all adjusted for age, sex, calendar year, smoking, diabe-
tes, pretreatment systolic blood pressure, duration of hypertension, physical activity, and education.
Drug
Dose
No. of
Cases
No. of
Controls
Diuretics 99 452
Calcium Channel Blockers
Low 1 7 70
Medium 22 69
High 17 31
Diuretics and Calcium Channel Blo
Low 7 24
Medium 8 22
High 9 14
Adjusted Adjusted
RR (95% CI) RR and 95% CI
Treatment
, Better
1.0 (Reference)
1.15 (0.62-2.14)
1.46(0.82-2.62)
2.88(1.46-5.67)
ckers
0.98 (0.38-2.53)
1.67(0.69-4.03)
3.33 (1.33-8.34)
l
Treatment
Worse
|
l
1
i
l
0.5 1.0 30 90
Figure 2 —Association between myocardial infarction and dose of calcium channel blockers among subjects
without any clinical cardiovascular disease. RR mdicates risk ratio (boxes); CI, confidence interval (cross
bars) All RRs were adjusted for the same factors listed m the legend to Figure 1. P values for the test for
trend were .003 among single-drug users of calcium channel blockers and .008 among users of diuretics
plus calcium channel blockers. The RRs in the figure are on a logarithmic scale.
tions for CVD also affected the results
in only trivial ways. Neither the divi-
sion of diuretic users into those who did
and did not also use a potassium-sparing
agent nor the division of diuretic users
into dosage groups had any effect on the
results. Gase fatality rates were similar
in subjects taking calcium channel block-
ers compared with subjects taking
ß-blockers (risk ratio=0.95; 95% CI, 0.51
to 1.76).
COMMENT
In this population-based case-control
study, the use of calcium channel blockers
äs antihypertensive therapy was consis-
tently associated with about a 60% in-
crease in the risk ratio for incident myo-
cardial infarction. The association per-
sisted after we controlled for many known
risk factors for myocardial infarction: it
was independent of the reference group
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Drug
Dose
(i-Blockers
Low
Medium
High
CVD CVD
Absent, Present,
RR RR
1 00
085
078
1 00
093
070
Adjusted Adjusted
All Subjects, All Subjects,
RR (95% Cl) RR and 95% Cl
Treatment
l Better
1
,
1 00 (Reference) ! — ι
0 88 (0 62-1 25) \ —m-
i
073(047-1 14) t ,
Calcium Channel Blockers i
Low
Medium
High
1 07
1 41
2 11
1 17
1 54
1 72
1 13 (n 7^-1 71)
1 42 (0 97-2 07) \
£
1 81 (1 20-2 75)
i
Treatment t
Worse s
1
*
l i
— 3
s
i
05 1 0 20
Figure 3 —Association between myocardial mfarction and use of calcium channel blockers compared with
the Iow-dose users of ß-blockers dose-response analysis stratified by the presence or absence of clmical
cardiovascular disease (CVD) RR mdicates nsk ratio (boxes), Cl, confidence mterval (cross bars) Among
subjects without CVD, the RRs were adjusted for the factors hsted m the legend of Figure 1 Among sub-
jects with CVD and among all subjects, the RR was adjusted not only for age, sex, calendar year smokmg,
diabetes, pretreatment systolic blood pressure, duration of hypertension physical activity, and education,
but also for the clmical CVD charactenstics of angma, stroke, claudication, coronary angioplasty, coronary
bypass surgery, peripheral vascular surgery, carotid endarterectomy, and recent use of nitroglycenn For
all subjects, Pvalues for the tests for trend were 035 for ß-blockers and 003 for calcium channel blockers
(Figures l through 3); it was specific to
calcium channel blockers but not ß-block-
ers or ACE Inhibitors, either alone or in
combination with diuretics; it was consis-
tent across multiple subgroups; and it was
most pronounced among subjects taking
high doses of calcium channel blockers.
The dose-response findings were not only
statistically significant, but they also went
in opposite directions for ß-blockers and
calcium channel blockers (Figure 3). The
dose-response findings for calcium chan-
nel blockers and myocardial infarction in
thife study are similar to the dose-response
findings for short-acting nifedipine and
mortality in a meta-analysis of secondary
prevention trials.15
The strengths of this observational
study include the use of population-based
cases and controls, the completeness of
case identification, the valiclation of case
diagnosis, the comparable ascertainment
of potential confounding factors, and the
use of the GHC pharmacy database to
assess antihypertensive therapy in a
comparable and unbiased fashion. Re-
btriction, stratification, and adjustment
were used to minimize the possibility of
confounding. All subjects, moreover,
were enrollees of a health maintenance
organization and thus had similar access
to health care.
Well-designed case-control studies can
complement the clinical trials.2 In part
because a large number of alternative
therapies are available and commonly
used, antihypertensive therapy is well
suited to an outcome evaluation by ob-
servational methods. The high degree of
similarity in treatment regimens between
controls with and without various clinical
characteristics (Table 2) not only mini-
mizes the possibility of important con-
founding by those characteristics, but also
provides some assurance of the validity of
the adjusted comparisons. As an obser-
vational study, the case-control design also
has several limitations. First, physicians
and patients selected antihypertensive
therapy, and this self-selection may have
introduced bias. Second, there may have
been unknown or unmeasured confound-
ing factors for which adjustment was not
possible. Third, measurement error in the
assessment or estimation of covariates and
their severity may have resulted in in-
complete adjustment and residual con-
founding. For instance, despite adjustment
for potential confounding factors, it is dif-
ficult to exclude the possibility that among
subjects free of clinical CVD (Figure 2),
higher doses of calcium channel blockers
were simply a marker for more severe
hypertension. Clmical trials, which are not
subject to these limitations, are impor-
tant because they can assess the overall
risk or benefit of a therapy in terms of a
variety of important cardiovascular out-
comes—not only myocardial infarction but
also stroke, congestive heart failure, and
renal disease.
Ideally, practitioners would like to base
clinical decisions on the results of ran-
domized clinical trials that include major
disease end points. Currently, approval
by the Food and Drug Administration
requires evidence of efficacy measured
solely in terms of the effect of antihyper-
tensive agents on a Surrogate end point—
the level of blood pressure. Clinical trial
data for the long-term safety and efficacy
of calcium channel blockers are lacking in
patients with high blood pressure.
Recent Conference reports summariz-
ing the results of two randomized clini-
cal trials suggest the possibility of härm
associated with the use of calcium chan-
nel blockers in hypertensive patients.Λ K
In a clinical trial designed to assess the
effects of antihypertensive therapy on
carotid atherosclerosis,51 "' subjects ran-
domized to isradipine and followed for 3
years had a higher rate of cardiovascu-
lar events than those randomized to a
hydrochlorothiazide (risk ratio=1.78; 95%
Cl, 0.94 to 3.38; P=.07). In another clini-
cal trial reported in Japan," 1017 hy-
pertensive patients randomized to a cal-
cium channel blocker had a significantly
higher incidence of cerebrovascular
events than the 1025 patients random-
ized to an ACE Inhibitor (risk ratio=3.0;
95% Cl, 1.1 to 8.3; P=.02). This finding
occurred despite a greater reduction in
the level of blood pressure among those
randomized to the calcium channel
blocker. These clinical trial data illus-
trate the crucial point that because drugs
have multiple effects, the use of blood
pressure may not be adequate äs a Sur-
rogate for the effect of antihypertensive
therapies on major disease end points.
There are several plausible explana-
tions for an adverse effect of the calcium
channel blockers seen in these studies1':
(1) negative inotropic effects; (2) proar-
rhythmic effects; (3) prohemorrhagic ef-
fects"; (4) proischemic effects from the
coronary steal phenomenon"; and (5) for
short-acting dihydropyridines, a reflex
increase in sympathetic activity,'6 one
which could theoretically produce plaque
rupture.!Y Multiple-day dosing required
of short-acting agents may also lead to
poorer compliance and control of blood
pressure. With the exception of the pre-
vention of restenosis after angioplasty,'s
the finding of an adverse effect of cal-
cium channel blockers in our study is
consistent with other recent reports of
the adverse effects of the extensively
studied short-acting dihydropyridine cal-
cium channel blockers.111'1()" "Λ 12
For nondihydropyridine calcium chan-
nel blockers,12 the secondary prevention
trials have shown no effect on mortality
(risk ratio=0.95; 95% Cl, 0.82 to 1.09)
and a reduction in reinfarction (risk ra-
tio=0.79; 95% Cl, 0.67 to 0.94). While the
results of the secondary prevention tri-
als might have suggested a difference
between dihydropyridine and nondihy-
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dropyndme calcium channel blockers,
the nsks of a first myocardial infarction
associated with the three major sub-
classes of the short-actmg calcmm chan-
nel blockers m this study were similar
Whether the long-actmg formulations
and other specific calcium channel block-
ers will have beneficial or adverse ef-
fects on the mcidence of CVD remams
to be seen. These questions reqmre em-
pinc evidence from additional studies.
In this case-control study, the use of
calcium channel blockers, especially m high
doses, was associated with an mcrea&ed
nsk of myocardial infarction For calcium
channel blockers used m low doses (Fig-
ures 2 and 3), the association was small
and close to l 0 These fmdmgs provide
mchrect Support to the fifth report of the
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